Skip to main content
VIYASH SCIENTIFIC LIMITED logo

VIYASH SCIENTIFIC LIMITED — Investor Relations & Filings

Ticker · VIYASH ISIN · INE807F01027 LEI · 335800SXM7D3VSHF2X07 BSE.NS Manufacturing
Open in API
Filings indexed 1,424 across all filing types
Latest filing 2025-02-11 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS VIYASH

About VIYASH SCIENTIFIC LIMITED

https://www.viyash.com

Viyash Scientific Limited is an integrated pharmaceutical platform specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and finished dosage forms. The organization operates a network of manufacturing facilities supported by robust research and development capabilities, focusing on complex chemistry and niche therapeutic segments. Its core business activities encompass the entire pharmaceutical value chain, from process development and scale-up to commercial-scale production. The company provides integrated solutions to global partners, leveraging its technical expertise in chemical synthesis and commitment to international quality standards. By maintaining a focus on operational excellence and innovation, the company serves as a strategic partner in the global healthcare supply chain, delivering high-quality medicinal components and formulations.

Recent filings

Filing Released Lang Actions
Pursuant to Regulation 30 and Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors at ....
Interim / Quarterly Report Classification · 93% confidence The document is a regulatory filing by SeQuent Scientific Limited announcing the Board’s approval of unaudited standalone and consolidated financial results for the quarter and nine-month period ended December 31, 2024. It includes the full interim financial statements and the limited review auditor’s report, satisfying the criteria for a comprehensive interim/quarterly report rather than a brief earnings highlight or simple announcement. Therefore, it should be classified as an Interim / Quarterly Report. 9M 2024
2025-02-11 English
Pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly note ....
Regulatory Filings Classification · 95% confidence The document is a notification about a scheduled conference call to discuss the company's Q3FY25 financial results. It references the upcoming earnings call date and provides dial-in details and speaker information. There is no actual financial data or detailed financial report included in the text. The document is short (2105 characters) and serves as an announcement of the conference call rather than the transcript or report itself. Therefore, it fits the definition of a Call Transcript (CT) only if it contained the full transcript, but since it is only an intimation of the call, it is best classified as a Regulatory Filing (RNS) as a general announcement. However, given the options, the closest specific category is Call Transcript (CT) if the document were the transcript, but since it is only an intimation, it is not a transcript. The best fit is Regulatory Filings (RNS) as a general announcement of the conference call.
2025-02-06 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a notice of a scheduled conference call to discuss the Q3FY25 financial results of Sequent Scientific Limited. It includes details about the date, time, and participants of the call, but does not contain any actual financial data or results. The document is an announcement of the conference call, not the transcript or the earnings release itself. Therefore, it fits the category of a Call Transcript (CT) announcement or invitation. However, since it is only an intimation of the conference call and not the transcript, the best fitting category is Call Transcript (CT) as it relates directly to the conference call content. Confidence is high due to clear mention of conference call and Q3FY25 results discussion.
2025-02-06 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-02-04 English
SEQUENT SCIENTIFIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 ,inter alia, to consider and approve Meeting of the Board of ....
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming Board Meeting scheduled to consider and approve the company's unaudited financial results for the quarter and nine months ended December 31, 2024. It references Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of events or information by listed entities. The document does not contain the financial results themselves but informs about the meeting date and trading window closure related to the results announcement. The document length is short (1808 characters) and serves as an announcement rather than the report itself. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and disclosure rather than an Interim Report (IR) or Earnings Release (ER).
2025-02-04 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges about an upcoming Board Meeting scheduled to approve the unaudited financial results for the quarter and nine months ended December 31, 2024. It references Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about board meetings. The document does not contain the financial results themselves but informs about the meeting where these results will be considered and approved. The document length is short (1808 characters) and serves as an announcement rather than a report. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a board meeting and upcoming financial results, not the results or report itself.
2025-02-04 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.